Authors:
- Alecia Clary , Ph.D., MSW (AC) (Corresponding author)Affiliation: The Reagan-Udall Foundation for the FDA, Washington, DC,
USA
Address: 1333 New Hampshire Ave, NW Suite 420, Washington DC 20036,
USA
Email:
aclary@reaganudall.org
Phone: 202-849-2075
ORCID ID: 0000-0002-7774-9808
- Nancy D Lin , (NDL)
Affiliation: IQVIA Real World Solutions, Bridgewater, NJ, USA
Address: 77 Corporate Drive, Bridgewater, NJ 08807
Email: Nancy.lin@iqvia.com
- Tamar Lasky , (TL)
Affiliation: The United States Food and Drug Administration, Office of
Data, Analytics, & Research, Office of the Commissioner, Washington
DC, USA
Address: 10903 New Hampshire Avenue, Silver Spring, MD, USA.
Email: Tamar.lasky@fda.hhs.gov
- Matthew W Reynolds , (MR)
Affiliation: IQVIA Real-World Solutions, Washington, DC, USA
Address: 201 Broadway, Cambridge, MA, USA.
Email: Matthew.Reynolds@IQVIA.com
- Anand Chokkalingam , (ACH)
Affiliation: Gilead Sciences, Foster City, California, USA
Address: 333 Lakeside Drive
Email: Anand.Chokkalingam@gilead.com
- Carla Rodriguez-Watson, (CRW)Affiliation: The Reagan-Udall Foundation for the FDA, Washington, DC,
USA
Address: 1333 New Hampshire Ave, NW Suite 420, Washington DC 20036,
USA
Email:
crodriguezwatson@reaganudall.org
This paper has not been previously printed, currently has not been
submitted for publication in any other journal and is not pending
acceptance in any other journal. We have not had any prior
correspondence with the journal about the manuscript.